Institutional Review of Compliance With NCCN Guidelines for Breast Cancer: Lessons Learned From Real-Time Multidimensional Synoptic Reporting

Adegboyega, Titilayo; Landercasper, Jeffrey; Linebarger, Jared H.; Johnson, James C.; Andersen, Jeremiah J.; Dietrich, Leah L.; Driscoll, Collin; Raghavendra, Meghana; Madadi, Anusha R.; Al-Hamadani, Mohammed; Vang, Choua A; Marcou, Kristen A.; Hudak, Jane; Go, Ronald S.

doi:10.6004/jnccn.2015.0026

Cited by 15 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The histopathological diagnosis for breast tumor was made according to cellular morphological changes and tissue architecture by using previously established criteria. [29][30][31] Fifty-two out of one hundred thirty-four IBCa were graded as well-differentiated (38.8%), 52/134 were moderately-differentiated (38.8%) and the rest (30/134) were poorly-differentiated (22.3%). The TNM stage of invasive carcinomas was also assessed following the 2012 WHO classification of breast tumors.…”

Section: Tumor Tissuesmentioning

confidence: 99%

“…The TNM stage of invasive carcinomas was also assessed following the 2012 WHO classification of breast tumors. 29,30 Carcinoma specimens were classified as stage T1 (40/134, 29.9%), T2 (51/134, 38.1%), T3 (31/134, 23.1%) and T4 (12/134, 9.0%). In addition, local lymph node metastasis occurred in 53 cases of 134 cases (39.6%) (Table S1).…”

Section: Tumor Tissuesmentioning

confidence: 99%

“…HER2 expression was scored according to the guidelines of the National Comprehensive Cancer Network. 30,32 Positivity of HER-2 was scored as "CC" when strong and complete membrane staining was present in more than 30% of invasive tumor cells. 30,32 Peripheral blood cells and fresh tissues samples Peripheral blood cells were collected from IBCa and fibroadenoma patients as well as healthy individuals for flow cytometry analysis of cell surface markers.…”

Section: Tumor Tissuesmentioning

confidence: 99%

“…30,32 Positivity of HER-2 was scored as "CC" when strong and complete membrane staining was present in more than 30% of invasive tumor cells. 30,32 Peripheral blood cells and fresh tissues samples Peripheral blood cells were collected from IBCa and fibroadenoma patients as well as healthy individuals for flow cytometry analysis of cell surface markers. Age-matched patients with IBCa, fibroadenoma patients and female health individuals were included in this study as disease control.…”

Section: Tumor Tissuesmentioning

confidence: 99%

See 3 more Smart Citations

PD-L1 mediated the differentiation of tumor-infiltrating CD19⁺B lymphocytes and T cells in Invasive breast cancer

et al. 2015

View full text Add to dashboard Cite

Accumulating evidence suggests that B cells play important roles in inhibiting the immune response in autoimmune disorders and human tumors as well as murine tumor models. In an effort to explore the role of B cells in human breast cancer etiology, we examined the presence of CD19 C B lymphocytes in 134 cases of invasive breast carcinoma (IBCa) and 31 breast fibroadenoma, and assessed its relationship with PD-L1 (programmed death-ligand 1) expression in breast cancer. We found that the density of CD19 C B lymphocytes was higher in IBCa compared with fibroadenoma, and significantly associated with increasing tumor grade, negative estrogen status. Similar findings were observed for the expression of IL-10 in IBCa. Meanwhile, CD19C B lymphocytes were shown to be highly coincident with PD-L1 and IL-10 in IBCa. We further demonstrated that CD19 C B cells can differentiate into CD19 Foxp3C T cells by CD19 C B cells was further shown to be mediated by PD-L1. Together, these results are suggestive of a role for CD19 C B lymphocytes in immune suppression and tumor evasion via PD-L1 in breast cancer.

show abstract

Section: Tumor Tissuesmentioning

confidence: 99%

Section: Tumor Tissuesmentioning

confidence: 99%

Section: Tumor Tissuesmentioning

confidence: 99%

Section: Tumor Tissuesmentioning

confidence: 99%

See 2 more Smart Citations

PD-L1 mediated the differentiation of tumor-infiltrating CD19⁺B lymphocytes and T cells in Invasive breast cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A total of 30 healthy individuals (mean age 52.3±5.8 years) served as the healthy control. The diagnosis of breast cancer was performed according to the pathological report as revealed in the guidelines proposed by the National Comprehensive Cancer Network (12). Patients with severe organ failure or history of carcinoma were excluded from the study.…”

Section: Methodsmentioning

confidence: 99%

Identification of CD4+CD25+CD127− regulatory T cells and CD14+HLA−DR−/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer

Wang

Yang

2016

Biomedical Reports

View full text Add to dashboard Cite

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations

Hendriks

Verbeek

Manen

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose EUSOMA's recommendation that "each patient has to be fully informed about each step in the diagnostic and therapeutic pathway" could be supported by guideline-based clinical decision trees (CDTs). The Dutch breast cancer guideline has been modeled into CDTs (www.oncog uide.nl). Prerequisites for adequate CDT usage are availability of necessary patient data at the time of decision-making and to consider all possible treatment alternatives provided in the CDT. Methods This retrospective single-center study evaluated 394 randomly selected female patients with non-metastatic breast cancer between 2012 and 2015. Four pivotal CDTs were selected. Two researchers analyzed patient records to determine to which degree patient data required per CDT were available at the time of multidisciplinary team (MDT) meeting and how often multiple alternatives were actually reported. Results The four selected CDTs were indication for magnetic resonance imaging (MRI) scan, preoperative and adjuvant systemic treatment, and immediate breast reconstruction. For 70%, 13%, 97% and 13% of patients, respectively, all necessary data were available. The two most frequent underreported data-items were "clinical M-stage" (87%) and "assessable mammography" (28%). Treatment alternatives were reported by MDTs in 32% of patients regarding primary treatment and in 28% regarding breast reconstruction. Conclusion Both the availability of data in patient records essential for guideline-based recommendations and the reporting of possible treatment alternatives of the investigated CDTs were low. To meet EUSOMA's requirements, information that is supposed to be implicitly known must be explicated by MDTs. Moreover, MDTs have to adhere to clear definitions of data-items in their reporting. Keywords Guidelines • Clinical decision trees • Decision support • Breast cancer • Multidisciplinary team Abbreviations AST Adjuvant systemic treatment CDT Clinical decision tree EUSOMA European Society of Breast Cancer Specialists IBR Immediate breast reconstruction MDT Multidisciplinary team MRI Magnetic resonance imaging PST Preoperative systemic treatment TNM Tumor (T), nodes (N) and metastases (M) Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Institutional Review of Compliance With NCCN Guidelines for Breast Cancer: Lessons Learned From Real-Time Multidimensional Synoptic Reporting

Cited by 15 publications

References 15 publications

PD-L1 mediated the differentiation of tumor-infiltrating CD19⁺B lymphocytes and T cells in Invasive breast cancer

PD-L1 mediated the differentiation of tumor-infiltrating CD19⁺B lymphocytes and T cells in Invasive breast cancer

Identification of CD4+CD25+CD127− regulatory T cells and CD14+HLA−DR−/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations

Contact Info

Product

Resources

About

Institutional Review of Compliance With NCCN Guidelines for Breast Cancer: Lessons Learned From Real-Time Multidimensional Synoptic Reporting

Cited by 15 publications

References 15 publications

PD-L1 mediated the differentiation of tumor-infiltrating CD19+B lymphocytes and T cells in Invasive breast cancer

PD-L1 mediated the differentiation of tumor-infiltrating CD19+B lymphocytes and T cells in Invasive breast cancer

Identification of CD4+CD25+CD127− regulatory T cells and CD14+HLA−DR−/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer

Clinical decision trees support systematic evaluation of multidisciplinary team recommendations

Contact Info

Product

Resources

About

PD-L1 mediated the differentiation of tumor-infiltrating CD19⁺B lymphocytes and T cells in Invasive breast cancer

PD-L1 mediated the differentiation of tumor-infiltrating CD19⁺B lymphocytes and T cells in Invasive breast cancer